Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 2, 2013F1000Prime ReportsOpen Access

BRAF inhibitors in clinical oncology

View Full Paper
Ask AI
Bookmark
Share

Authors

VMVan K. MorrisThe University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott KopetzDartmouth College

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Morris et al. (2013) studied this question.

synapsesocial.com/papers/6ab8afdb71d168da348b4da0https://doi.org/10.12703/p5-11
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases1997 · 467 citations
  2. 2Braf and erbB2 mutations correlate with smoking status in lung cancer patients2012 · 28 citations
  3. 3BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum2004 · 726 citations
  4. 4Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status2011 · 1,898 citations